CGAS Gene Variant Tied to Healthy Aging in Long-Lived
SkimNews Take
The standout CGAS finding reinforces inflammation—not the dozen other variants—as the most actionable lead, suggesting longevity interventions will converge on dampening immune signaling rather than correcting rare mutations.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Pasquale Putter presented the intergenerational aging study at the European Society of Human Genetics conference in Gothenburg, reporting that middle-aged individuals with long-lived parents developed cardiometabolic diseases 13 years later than partners whose parents had shorter lifespans.
- Leiden University Medical Center researchers analyzed genomes of 212 long-lived sibships from the Leiden Longevity Study, narrowing 20,000 genes down to 350 candidates across four genomic regions and ultimately 12 rare protein-altering variants tied to longer healthspan.
- A variant in the CGAS (cyclic GMP-AMP synthase) gene, which triggers inflammation when DNA is detected outside its proper location in a cell, appeared in two long-lived families; carriers likely had only one active copy, reducing inflammatory response while preserving infection-clearing ability.
- Researchers say completely shutting down the CGAS pathway could increase vulnerability to infections and cancer, while overactivation drives chronic inflammation and tissue damage — making the partial-reduction effect found in these families a narrow therapeutic window.
- The team is next introducing the CGAS mutation into killifish at the Max Planck Institute for the Biology of Ageing in Cologne; the species' 3-to-9-month natural lifespan allows rapid testing of whether the mutation extends lifespan and improves tissue health versus controls.
- Professor Alexandre Reymond, chair of the conference and not involved in the study, said the findings point to 'key elements to extend the healthspan of all.'
Why it matters: By shifting from studying individual supercentenarians to entire long-lived families — where environmental and lifestyle factors are partially shared — the Leiden team isolated 12 rare variants, including a CGAS mutation that tames inflammation without disabling immune defense. That mechanistic sweet spot is exactly the kind of target drug developers need to extend disease-free years in the general aging population.
